Theratechnologies Inc. re-affirmed revenue guidance for the fiscal year of 2022. For the year, the company is on track to be in the range of $79 million - $82 million, or growth of the commercial portfolio to be in the range of 13% and 17%, as compared to the 2021 fiscal year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.66 CAD | -2.92% | -6.21% | -22.43% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.43% | 56.03M | |
-1.62% | 90.85B | |
-1.05% | 39.02B | |
-11.20% | 33.46B | |
-20.75% | 14.51B | |
-6.35% | 13.22B | |
-11.42% | 11.65B | |
-47.67% | 10.57B | |
+6.37% | 9.23B | |
+102.03% | 7.71B |
- Stock Market
- Equities
- TH Stock
- News Theratechnologies Inc.
- Theratechnologies Inc. Re-Affirms Revenue Guidance for the Fiscal Year of 2022